Cruise, GM's AV subsidiary, resumed supervised robotaxi operations in 2025 after a 2023 regulatory pause, focusing on Phoenix and Nashville markets.
Surgical robots, AI diagnostics, and automated laboratory systems transforming healthcare delivery globally. Cruise (GM)'s automation score of 10 reflects its R&D intensity ($2.0B annually) and AI patent portfolio of 760 patents.
| # | Company | Automation Score | AI Patents | R&D ($B) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 3100 | $1.2B | |
| 2 | Stryker Mako | 680 | $0.9B | |
| 3 | Medtronic Hugo | 420 | $0.55B | |
| 4 | CMR Surgical | 310 | $0.35B | |
| 5 | Accuray | 210 | $0.12B |